STOCK TITAN
  1. Home
  2. Sec-filings
  3. GYRE
  4. [Form 4] GYRE THERAPEUTICS, INC. Insider Trading Activity

CEO of Gyre Therapeutics (NASDAQ: GYRE) receives 120,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. reported that Chief Executive Officer Luo Ying received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $6.05 per share and expire on June 8, 2036.

According to the grant terms, 25% of the options will vest on June 8, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Luo Ying’s continued service. Following this award, the filing shows 120,000 derivative securities held directly.

Positive

  • None.

Negative

  • None.
Insider Luo Ying
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 120,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 120,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 120,000 options Stock Option (Right to Buy) granted to CEO on June 8, 2026
Exercise price $6.05 per share Conversion or exercise price of granted options
Expiration date June 8, 2036 Option expiration for CEO grant
Underlying shares 120,000 shares Common stock underlying the option grant
Post-grant derivative holdings 120,000 derivatives Total derivative securities following transaction
Initial vesting tranche 25% on June 8, 2027 First vesting date and proportion of options
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 6.0500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Luo Ying
(Last)(First)(Middle)
C/O GYRE THERAPEUTICS, INC.
12730 HIGH BLUFF DRIVE, SUITE 250
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$6.0506/08/2026A120,000 (1)06/08/2036Common Stock120,000$0120,000D
Explanation of Responses:
1. This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
/s/ Thomas Eastling, as attorney-in-fact for Ying Luo06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did GYRE CEO Luo Ying report in this Form 4?

Luo Ying reported receiving a stock option grant for 120,000 shares of Gyre Therapeutics common stock at a $6.05 exercise price, expiring June 8, 2036, as part of equity-based compensation.

How many stock options did GYRE grant to its CEO?

Gyre Therapeutics granted CEO Luo Ying options for 120,000 underlying common shares. These options vest over four years, beginning with 25% on June 8, 2027, then monthly installments for the remaining three years.

What is the exercise price of Luo Ying’s GYRE stock options?

The exercise price of Luo Ying’s stock options is $6.05 per share. This is the price at which the CEO can purchase Gyre Therapeutics common stock once the options vest and are exercisable.

When do the GYRE CEO stock options vest?

Twenty-five percent of the options vest on June 8, 2027. The remaining 75% vest in equal monthly installments over the next three years, contingent on Luo Ying’s continued service with Gyre Therapeutics.

How many derivative securities does the GYRE CEO hold after this grant?

After this grant, the Form 4 shows Luo Ying holding 120,000 derivative securities. These represent stock options giving the right to buy an equal number of Gyre Therapeutics common shares if exercised.